Publications by authors named "Pizzarotti B"
Article Synopsis
- In 2023, lecanemab was introduced as a new treatment for Alzheimer's disease, showcasing advancements in Alzheimer's care.
- New biomarkers have significantly improved the diagnosis and monitoring of conditions like peripheral neuropathies and synucleinopathies.
- Research has unveiled the impact of genetic factors in multiple sclerosis progression, while new migraine treatments and expanded thrombectomy criteria are enhancing patient care in neurology.
Obstructive sleep apnea syndrome (OSA) may be a risk factor for Alzheimer's disease. One of the hallmarks of Alzheimer's disease is disturbed iron homeostasis leading to abnormal iron deposition in brain tissue. To date, there is no empirical evidence to support the hypothesis of altered brain iron homeostasis in patients with obstructive sleep apnea as well.
View Article and Find Full Text PDFObjective: Coronavirus disease (COVID-19) has been associated with a large variety of neurologic disorders. However, the mechanisms underlying these neurologic complications remain elusive. In this study, we aimed at determining whether neurologic symptoms were caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) direct infection or by either systemic or local proinflammatory mediators.
View Article and Find Full Text PDFFrontal and Cerebellar Atrophy Supports FTSD-ALS Clinical Continuum.
Front Aging Neurosci
November 2020
Background: Frontotemporal Spectrum Disorder (FTSD) and Amyotrophic Lateral Sclerosis (ALS) are neurodegenerative diseases often considered as a continuum from clinical, epidemiologic, and genetic perspectives. We used localized brain volume alterations to evaluate common and specific features of FTSD, FTSD-ALS, and ALS patients to further understand this clinical continuum.
Methods: We used voxel-based morphometry on structural magnetic resonance images to localize volume alterations in group comparisons: patients (20 FTSD, seven FTSD-ALS, and 18 ALS) versus healthy controls (39 CTR), and patient groups between themselves.
Objective: Serotonergic appetite suppressants and ergot-derived dopamine agonists have been associated with drug-induced valvular heart disease. The purpose of this meta-analysis is to synthesise the current evidence of a link between several medications affecting sertonergic pathways and valvular heart disease.
Methods: PubMed was searched to identify studies evaluating an association between medications with serotonergic activity and cardiac valvular pathology.